http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research
-
Veracyte to Participate in Upcoming Investor Conferences
-
Veracyte Announces First Quarter 2025 Financial Results
-
Veracyte (VCYT) Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
-
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
-
Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting
-
Veracyte (VCYT) Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release
-
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release
-
Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025
-
New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer
-
Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25
-
Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results
-
Veracyte to Participate in Upcoming Investor Conferences
-
New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research
-
Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium
-
New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer
-
Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025
-
Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines
-
Veracyte Announces Third Quarter 2024 Financial Results
-
Veracyte to Participate in Upcoming Investor Conferences
-
Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024
-
New Data Presented at ASTRO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men
-
New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
-
Veracyte (VCYT) Appoints Brent Shafer and Tom Miller to its Board
-
Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors
-
Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
-
Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle
-
Veracyte Announces Second Quarter 2024 Financial Results
-
Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024
-
Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors
-
Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
-
Veracyte to Participate in Upcoming Investor Conferences
-
Veracyte Announces First Quarter 2024 Financial Results
-
14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
-
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
-
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
-
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
-
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
-
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
-
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
-
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
-
Veracyte Completes Acquisition of C2i Genomics
-
Veracyte (VCYT) Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics
-
Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
-
Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
-
Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
-
Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules
-
Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023
-
Veracyte Announces Third Quarter 2023 Financial Results
-
Veracyte (VCYT) Announces In Vitro Diagnostic Agreement with Illumina (ILMN) to Broaden Availability of Its Tests for Patients Globally
